Sun Pharmaceutical Industries has introduced its blockbuster biologic therapy Ilumya (Tildrakizumab) in India, marking a major step toward expanding access to advanced treatments for moderate-to-severe plaque psoriasis. Known for selectively targeting IL-23, Ilumya has already made its mark across 35 global markets, including the United States, and is now set to benefit Continue Reading
